News
SNPHF
10.99
NaN%
--
Santen Completes Treasury Share Disposal for Performance-Linked Executive Stock Plan
TipRanks · 5d ago
Santen to Dispose of Treasury Shares for Performance-Linked Executive Stock Plan
TipRanks · 09/03 07:24
Santen boosts profits in Q1 and maintains upbeat full-year outlook
TipRanks · 08/06 07:21
Santen Pharmaceutical Co (SNPHF) Gets a Buy from UBS
TipRanks · 07/14 12:46
Santen Pharmaceutical Lifts Earnings and Dividends, Signals Growth for FY2027
TipRanks · 05/12 07:59
Santen Pharmaceutical Posts Lower Nine-Month Earnings but Raises Annual Dividend and Maintains Outlook
TipRanks · 02/05 07:05
Santen Pharmaceutical Reports Decline in Financial Performance but Maintains Dividend Strategy
TipRanks · 11/06/2025 07:10
Santen Pharmaceutical to Cancel 19.8 Million Treasury Shares
TipRanks · 11/06/2025 07:10
Santen Completes Share Buyback to Enhance Shareholder Value
TipRanks · 11/06/2025 07:10
Santen Pharmaceutical Updates on Share Buyback Progress
TipRanks · 11/04/2025 07:42
Santen Completes Disposal of Treasury Shares for Stock Remuneration Plan
TipRanks · 10/31/2025 08:37
Santen Pharmaceutical Co (SNPHF) Receives a Buy from Goldman Sachs
Barchart · 10/11/2025 06:26
More
Webull provides a variety of real-time SNPHF stock news. You can receive the latest news about Santen Pharmaceutical Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SNPHF
Santen Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, and sale of pharmaceuticals. The Company engages in global research and development, manufacture, sale, and marketing of pharmaceuticals in the ophthalmology field. The Company engages in prescription pharmaceuticals, over-the-counter pharmaceuticals, medical devices, and other businesses. The Company operates in Japan, Asia, Europe, the Middle East, and Africa (EMEA), China, and other regions.